Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study

Figure 4

Expression of DN-PP2Acα driven by the AFpg promoter selectively induces cytotoxic effects in AFP-positive HCC cells in vitro and in vivo. (A) Cells were transducted with recombinant adenoviruses at various MOI levels. At 12 h, 24 h, and 48 h post-infection, the MTT assay was performed. (B) Cells were transducted with recombinant adenoviruses at a MOI of 100. After 10 days, the number of visible colonies were counted. (C) Effect of AFpg promoter-driven DN-PP2Acα expression on the growth of implanted SK-Hep-1 and HepG2 tumors in athymic mice. Adenoviral gene therapy was initiated when tumors attained a volume of 100 mm3. Tumor volume was calculated as (length × width2)/2; *P < 0.05 and **P < 0.01 indicate significant differences compared to the control vehicle group.

Back to article page